LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 2 | G01 | 72 | hr | 1401 | 847 | 4223 | 0.2006 | -0.1965 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 3 | G01 | 72 | hr | 1401 | 665 | 4223 | 0.1575 | -0.2610 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 1 | P13 | 72 | hr | 1401 | 3300 | 4223 | 0.7814 | 0.6728 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 2 | P13 | 72 | hr | 1401 | 3190 | 4223 | 0.7554 | 0.6339 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 3 | P13 | 72 | hr | 1401 | 3164 | 4223 | 0.7492 | 0.6246 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 1 | A07 | 72 | hr | 1401 | 1124 | 4223 | 0.2662 | -0.0984 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 2 | A07 | 72 | hr | 1401 | 1535 | 4223 | 0.3635 | 0.0473 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 3 | A07 | 72 | hr | 1401 | 1535 | 4223 | 0.3635 | 0.0473 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 1 | I07 | 72 | hr | 1401 | 1821 | 4223 | 0.4312 | 0.1487 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 2 | I07 | 72 | hr | 1401 | 2121 | 4223 | 0.5022 | 0.2550 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 3 | I07 | 72 | hr | 1401 | 2137 | 4223 | 0.5060 | 0.2607 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 1 | A19 | 72 | hr | 1401 | 1018 | 4223 | 0.2411 | -0.1359 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 2 | A19 | 72 | hr | 1401 | 1214 | 4223 | 0.2875 | -0.0665 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 3 | A19 | 72 | hr | 1401 | 1487 | 4223 | 0.3521 | 0.0303 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 1 | P07 | 72 | hr | 1401 | 1496 | 4223 | 0.3542 | 0.0335 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 2 | P07 | 72 | hr | 1401 | 1697 | 4223 | 0.4018 | 0.1047 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 3 | P07 | 72 | hr | 1401 | 1705 | 4223 | 0.4037 | 0.1076 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 1 | D01 | 72 | hr | 1401 | 1545 | 4223 | 0.3659 | 0.0508 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 2 | D01 | 72 | hr | 1401 | 1767 | 4223 | 0.4184 | 0.1295 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 3 | D01 | 72 | hr | 1401 | 2000 | 4223 | 0.4736 | 0.2121 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 1 | I01 | 72 | hr | 1401 | 724 | 4223 | 0.1714 | -0.2401 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 2 | I01 | 72 | hr | 1401 | 1141 | 4223 | 0.2702 | -0.0923 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 3 | I01 | 72 | hr | 1401 | 835 | 4223 | 0.1977 | -0.2008 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 1 | E19 | 72 | hr | 1401 | 1615 | 4223 | 0.3824 | 0.0757 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 2 | E19 | 72 | hr | 1401 | 1967 | 4223 | 0.4658 | 0.2004 |